| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | SELL | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 6.49▲ | 6.47▲ | 6.48▲ | 6.68▼ | 6.29▲ |
| MA10 | 6.49▲ | 6.48▲ | 6.51▼ | 6.53▼ | 5.92▲ |
| MA20 | 6.47▲ | 6.49▲ | 6.60▼ | 6.29▲ | 5.19▲ |
| MA50 | 6.50▼ | 6.64▼ | 6.63▼ | 5.75▲ | 4.44▲ |
| MA100 | 6.56▼ | 6.57▼ | 6.39▲ | 5.17▲ | 3.56▲ |
| MA200 | 6.64▼ | 6.33▲ | 6.43▲ | 4.63▲ | 4.10▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.004▲ | 0.006▲ | -0.015▼ | -0.007▼ | 0.137▲ |
| RSI | 51.888▲ | 45.138▼ | 44.171▼ | 55.862▲ | 59.928▲ |
| STOCH | 39.899 | 41.316 | 44.570 | 77.303 | 72.762 |
| WILL %R | -36.364 | -44.737 | -70.930 | -47.679 | -24.169▲ |
| CCI | 16.867 | -3.215 | 0.216 | 25.826 | 85.970 |
|
Thursday, February 26, 2026 01:29 PM
February 26, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development ...
|
|
Thursday, February 26, 2026 01:28 PM
Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic ...
|
|
Friday, February 13, 2026 09:27 PM
CEO Andrew Obenshain said the company is preparing for a second-half phase 3 readout for lanifibranor in metabolic dysfunction-associated steatohepatitis (MASH), describing the trial as fully enrolled ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 27/02/26 | 6.47 | 6.63 | 6.39 | 6.49 | 180,255 |
| 26/02/26 | 6.85 | 6.85 | 6.36 | 6.55 | 356,966 |
| 25/02/26 | 6.85 | 7.055 | 6.765 | 6.82 | 394,396 |
| 24/02/26 | 6.82 | 6.85 | 6.62 | 6.79 | 165,130 |
| 23/02/26 | 6.56 | 6.82 | 6.49 | 6.74 | 0 |
| 20/02/26 | 6.51 | 6.77 | 6.44 | 6.75 | 667,834 |
| 19/02/26 | 6.39 | 6.72 | 6.32 | 6.70 | 409,845 |
| 18/02/26 | 6.14 | 6.353 | 6.05 | 6.17 | 243,884 |
| 17/02/26 | 6.13 | 6.14 | 5.95 | 6.08 | 309,681 |
| 13/02/26 | 6.11 | 6.26 | 6.0801 | 6.17 | 497,671 |
|
|
||||
|
|
||||
|
|